European Journal of Cancer
Volume 45, Issue 17 , Pages 2935-2939 , November 2009

Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importance

  • Boudewijn J.M. Braakhuis

      Affiliations

    • Section Tumor Biology, Department of Otolaryngology/Head–Neck Surgery, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: VU University Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands. Tel.: +31 (0)20 444 09 05: fax: +31 (0)20 444 20 33.
    • ,
  • Ruud H. Brakenhoff

      Affiliations

    • Section Tumor Biology, Department of Otolaryngology/Head–Neck Surgery, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Chris J.L.M. Meijer

      Affiliations

    • Section of Molecular Pathology, Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Peter J.F. Snijders

      Affiliations

    • Section of Molecular Pathology, Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • C. René Leemans

      Affiliations

    • Section Tumor Biology, Department of Otolaryngology/Head–Neck Surgery, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

Received 25 March 2009 ,Revised 20 August 2009 ,Accepted 21 August 2009.

References 

  1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72–81
  2. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. New Engl J Med. 2001;34:1125–1131
  3. Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol. 2009;21:201–205
  4. Braakhuis BJM, Snijders PJF, Keune WJH, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004;96:998–1006
  5. Smeets SJ, Braakhuis BJM, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25:2558–2564
  6. Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res. 2009;15:1779–1786
  7. Slebos RJC, Yi YJ, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:701–709
  8. Lohavanichbutr P, Houck J, Fan W, et al. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg. 2009;135:180–188
  9. Schlecht NF, Burk RD, Adrien L, et al. Gene expression profiles in hpv-infected head and neck cancer. J Pathol. 2007;213:283–293
  10. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer. 2007;43:415–432
  11. Melle C, Ernst G, Winkler R, et al. Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics. 2009;9:2193–2201
  12. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–720
  13. Gillison ML, D’souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–420
  14. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med. 2007;356:1944–1956
  15. Ragin CCR, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121:1813–1820
  16. Rosenquist K, Wennerberg J, Annertz K, et al. Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors. Acta Otolaryngol. 2007;127:980–987
  17. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772–1783
  18. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. 2005;14:467–475
  19. Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690–698
  20. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89:213–228
  21. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol. 1993;13:775–784
  22. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934–937
  23. Munger K, Basile JR, Duensing S, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001;20:7888–7898
  24. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 1995;9:2335–2349
  25. Snijders PJF, Steenbergen RDM, Heideman DAM. Meijer Cjlm. Hpv-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152–164
  26. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer. 2008;122:2656–2664
  27. Wittekindt C, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol. 2005;62:72–80
  28. Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. Cancer Res. 1993;53:1167–1171
  29. Steenbergen RD, Walboomers JM, Meijer CJ, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene. 1996;13:1249–1257
  30. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101:412–423
  31. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers. 2007;23:273–281
  32. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003;201:1–6
  33. Hesselink AT, van den Brule AJ, Brink AA, et al. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer. 2004;102:11–18
  34. Iftner T, Villa LL. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr. 2003;31:80–88
  35. van Ham MA, Bakkers JM, Harbers GK, et al. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol. 2005;43:2662–2667
  36. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998;153:1731–1739
  37. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791–795
  38. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357–361
  39. Clavel C, Masure M, Putaud I, et al. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol. 1998;51:737–740
  40. Hopman AH, Kamps MA, Smedts F, et al. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer. 2005;115:419–428
  41. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516–520
  42. Hesselink AT, van Ham MA, Heideman DA, et al. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol. 2008;46:3215–3221
  43. Cohen MA, Basha SR, Reichenbach DK, Robertson E, Sewell DA. Increased viral load correlates with improved survival in HPV-16-associated tonsil carcinoma patients. Acta Otolaryngol. 2008;128:583–589
  44. Van Houten VMM, Snijders PJF, Van Den Brekel MWM, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer. 2001;93:232–235
  45. Smeets SJ, Hesselink AT, Speel EJM, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121:2465–2472
  46. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–269
  47. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26:3138–3146
  48. Rosenquist K, Wennerberg J, Annertz K, et al. Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors. Acta Otolaryngol. 2007;127:980–987
  49. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92:805–813
  50. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24:5630–5636

PII: S0959-8049(09)00657-1

doi: 10.1016/j.ejca.2009.08.018

European Journal of Cancer
Volume 45, Issue 17 , Pages 2935-2939 , November 2009

Article Tools